A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy-Reference-Cited by-同舟云学术

A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Casadesús Ana Victoria¹²,Deligne Claire³,Diallo Béré Kadjdiatou⁴⁵,Sosa Katya¹²,Josseaume Nathalie⁶⁷⁸,Mesa Circe²,León Kalet⁹,Hernández Tays¹²,Teillaud Jean-Luc⁴⁵^ORCID

Affiliation:

1. Department of Chimeric Proteins, Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba

2. Immunobiology Division, Center of Molecular Immunology (CIM), Havana, Cuba

3. The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK

4. Sorbonne Université, Faculté De Médecine, UMRS 1135, Centre d’Immunologie Et Des Maladies Infectieuses Paris (Cimi-paris), Paris, France

5. Inserm U.1135, Immunology and Infectious Diseases Center (Cimi-paris), “Immune Microenvironment and Immunotherapy” Laboratory, Paris, France

6. Inserm U.1138, Cordeliers Research Center, Paris, France

7. UMRS 1138 Centre De Recherche Des Cordeliers, Sorbonne Université, Paris, France

8. Université Sorbonne Paris Cité, UMRS 1138, Centre De Recherche Des Cordeliers, Paris Descartes Université, Paris, France

9. Systems Biology Department, Center of Molecular Immunology, Havana, Cuba

Funder

CIFRE fellowship and Fondation Francaise pour la Recherche contre le Myelome et les Gammapathies

This work was supported by Inserm, Sorbonne university and Paris Descartes universiy

Ana Victoria Casadesús was supported by an EMBO short-term fellowship and by grants from the French Embassy in La Havana

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1770565

Reference54 articles.

1. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2. A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

3. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

4. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy;Frontiers in Immunology;2022-12-09

2. Rituximab Therapy for Primary Sjögren’s Syndrome;Frontiers in Pharmacology;2021-09-02